Table 1 Baseline characteristics of study patients
Characteristics | Total (N = 75) | MEE ( +) (N = 23) | No MEE (N = 52) | P-value |
|---|---|---|---|---|
Age, years | 45 (35–55) | 40 (33–51) | 47 (35–59) | 0.085 |
Sex | 0.602 | |||
Male | 36 (48.0) | 10 (43.5) | 26 (50.0) | |
Female | 39 (52.0) | 13 (56.5) | 26 (50.0) | |
Concurrent at diagnosis | ||||
Asthma | 73 (97.3) | 23 (100) | 50 (96.2) | 1.000 |
Peripheral neuropathy | 56 (74.7) | 16 (69.6) | 40 (76.9) | 0.499 |
PNS abnormalities | 56 (74.7) | 20 (87.0) | 36 (69.2) | 0.104 |
Extravascular eosinophils | 50 (66.7) | 15 (65.2) | 35 (67.3) | 0.859 |
Peripheral eosinophilia | 38 (50.7) | 13 (56.5) | 25 (48.1) | 0.500 |
Major organ involvement | ||||
Lung | 36 (48.0) | 12 (52.2) | 24 (46.2) | 0.630 |
Heart | 11 (14.7) | 2 (8.7) | 9 (17.3) | 0.486 |
Gastrointestinal tract | 9 (12.0) | 3 (13.0) | 6 (11.5) | 1.000 |
Kidney | 2 (2.7) | 0 | 2 (3.6) | 1.000 |
Brain | 2 (2.7) | 0 | 2 (3.6) | 1.000 |
Laboratory findingsa | ||||
Eosinophil counts (/μL) | 4430 (1746–7110) | 4892 (1791–7198) | 3875 (1381–7000) | 0.861 |
≥ 5000 /μL | 33 (44.0) | 8 (34.8) | 25 (48.1) | 0.285 |
ESR (mm/h) | 21 (10–39) | 28 (18–57) | 16 (8–39) | 0.044 |
CRP (mg/dL) | 0.6 (0.1–2.1) | 1.2 (0.1–3.6) | 0.5 (0.1–1.9) | 0.048 |
ANCA | 10 (13.9) | 0 | 10 (18.5) | 0.024 |
Total IgE (kU/L) | 397 (130–1236) | 710 (281–1596) | 396 (92–943) | 0.740 |
ECP (ug/L) | 52 (17–201) | 45 (17–114) | 59 (17–201) | 0.861 |
Systemic treatment regimen | 0.778 | |||
Cyclophosphamide | 57 (76.0) | 17 (73.9) | 40 (76.9) | |
Steroid only | 18 (24.0) | 6 (26.1) | 12 (23.1) | |